about
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.Recommendations for the diagnosis of pediatric tuberculosis.Recommendations for treating children with drug-resistant tuberculosis.Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe.Multidetector CT urography in urogenital tuberculosis: use of reformatted images for the assessment of the radiological findings. A pictorial essay.Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011.ERS/WHO tuberculosis consilium: reporting of the initial 10 cases.Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider.Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.Compassionate and optimum use of new tuberculosis drugs.How to manage children who have come into contact with patients affected by tuberculosisChallenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for EuropeTB consilia and quality of tuberculosis managementQuantiFERON-TB Performs Better in Children, Including Infants, than in Adults with Active Tuberculosis: a Multicenter StudySurveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
P50
Q30236048-12E17215-C88B-40C7-9CEE-00F9CA6E7CA9Q35909311-B748C9C6-22F8-4B51-B6AE-9A9B900C109DQ38609947-A719C893-E6BF-4A77-8E0A-D6F2A20DF051Q38715025-F1526FFA-5A1D-40BA-A4C1-5FD3009955B7Q39226043-9E7A7281-F11A-4C79-9576-ED29F350EDA5Q39227865-F797A50E-A701-4A01-B1D9-99BC5A6A76EDQ39524363-51F3F735-5EFB-4B0F-97DB-7DFBE7B1E33DQ40080040-BE31FF6C-E1C0-464A-9974-28EEAF8091C2Q40198478-A85893F3-C448-4B4E-A83C-EC3E2E793D27Q44493580-78AE4C4C-341A-463F-AE8A-A5C0AE26BE5FQ46671130-94BE88FC-F134-4F5E-9219-99B248C30273Q47683448-80B7FC72-0C54-47E4-A9C5-2A94EAC17F53Q49917864-5CF78DB0-368B-4489-BB23-8BEDCB56A9D6Q50560947-ABC602F1-2539-42CC-A327-0580AFA574C0Q51544855-7928202B-6D80-4A93-973F-91C6462EE524Q53813663-A787224B-53C1-4E31-B2AF-F617EB38B403Q56838135-757017E3-82DB-426B-A101-44E94193E15CQ62900361-2BD61DD7-86B6-48B0-AB4E-947B86735AE1Q64134813-AC01F878-8732-45AB-A858-D6EBF4D68C9AQ90806411-281DD0E1-90DF-4DE4-B7A8-5C770DB5D64FQ92481807-5EC1035A-CCFB-44D9-93EB-F628C1535DCCQ92891736-2EC06295-7F6F-432A-85D7-00C7D0FE75BE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Tadolini
@ast
Marina Tadolini
@en
Marina Tadolini
@es
Marina Tadolini
@nl
type
label
Marina Tadolini
@ast
Marina Tadolini
@en
Marina Tadolini
@es
Marina Tadolini
@nl
prefLabel
Marina Tadolini
@ast
Marina Tadolini
@en
Marina Tadolini
@es
Marina Tadolini
@nl
P106
P21
P31
P496
0000-0002-1005-7532